Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Clinical and MRI findings

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1979-1983

  Genovese, Mark C ^a   Yang, Fang ^b   Østergaard, Mikkel ^c   Kinnman, Nils ^b  

^a STANFORD UNIVERSITY   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

DMARDs (biologic); Magnetic Resonance Imaging; Rheumatoid Arthritis

Indexed keywords

C REACTIVE PROTEIN; DECERNOTINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; 2-((2-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YL)AMINO)-2-METHYL-N-(2,2,2-TRIFLUOROETHYL)BUTANAMIDE; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS; VALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; JOINT; MIDDLE AGED; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VALINE;

EID: 84964765486     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208901     Document Type: Article

References (17)

1. Ghoreschi K, Laurence A, OShea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
2. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.
3. Rane SG, Reddy EP. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994;9:2415-23.
4. Leonard WJ, OShea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
5. Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis 2014;73:1968-74.
6. Haavardsholm EA, Bøyesen P, Østergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800.
7. Hetland ML, Ejbjerg B, Hørslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
8. Døhn UM, Conaghan PG, Eshed I, et al. The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: intrareader and interreader reliability and agreement with computed tomography and conventional radiography. J Rheumatol 2014;41:392-7.
9. Baker JF, Conaghan PG, Emery P, et al. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann Rheum Dis 2016;75:1114-9.
10. Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015;67:334-43.
11. Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:46-55.
12. Østergaard M, Edmonds J, McQueen F, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image Atlas. Ann Rheum Dis 2005;64(Suppl 1):i3-7.
13. Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94.
14. Conaghan PG, Emery P, Østergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
15. Conaghan PG, Peterfy C, Olech E, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis 2014;73:810-16.
16. Østergaard M, Jacobsson LT, Schaufelberger C, et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis 2015;74:1156-63.
17. Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis 2016;75:170-7.